A 62-year-old woman with HFrEF (LVEF 28%) and hypertension is already on enalapril 10 mg daily and metoprolol 95 mg daily. She remains symptomatic with NYHA Class III dyspnea. Which agent should be added next to reduce mortality and improve symptoms?

Explanation

## Sequential Therapy in HFrEF: Adding a Mineralocorticoid Receptor Antagonist **Key Point:** After ACE-I and beta-blocker are optimized, **mineralocorticoid receptor antagonists (MRAs)** — spironolactone or eplerenone — are the next-line agent with proven mortality benefit in HFrEF. ### Mechanism of Benefit 1. **Aldosterone antagonism** — blocks aldosterone-mediated sodium retention, fibrosis, and arrhythmogenesis 2. **Reverse remodeling** — reduces left ventricular fibrosis and hypertrophy 3. **Potassium retention** — improves electrolyte balance in HF (paradoxically beneficial despite hyperkalemia risk) 4. **Mortality reduction** — landmark trials (RALES, EMPHASIS-HF) demonstrated 25–30% reduction in mortality ### Guideline Recommendation **High-Yield:** MRAs are **Class I, Level A** evidence for HFrEF patients already on ACE-I/ARB + beta-blocker, especially those with LVEF ≤35% or with prior MI [cite:Harrison 21e Ch 297]. ### Sequential Therapy Algorithm ```mermaid flowchart TD A["HFrEF diagnosed<br/>(LVEF ≤40%)"]:::outcome --> B["Start ACE-I/ARB<br/>+ Beta-blocker"]:::action B --> C{"Symptoms<br/>improved?"}:::decision C -->|Yes| D["Optimize doses<br/>Monitor"]:::action C -->|No| E["Add MRA<br/>(Spironolactone/Eplerenone)"]:::action E --> F{"Symptoms<br/>improved?"}:::decision F -->|Yes| G["Continue triple therapy"]:::action F -->|No| H["Add ARNI or SGLT2i"]:::action D --> I{"Deterioration?"}:::decision I -->|Yes| E ``` ### Comparison: MRA vs. Other Options | Agent | Class | Evidence | Role | Caution | |---|---|---|---|---| | **Spironolactone** | MRA | Class I, Level A | Second-line after ACE-I + BB | Hyperkalemia, gynecomastia | | **Eplerenone** | MRA (selective) | Class I, Level A | Alternative to spironolactone | Fewer hormonal side effects | | **Amlodipine** | CCB | Class III | Avoid in systolic HF | No mortality benefit; reflex tachycardia | | **Ivabradine** | I~f~ inhibitor | Class IIb | Adjunctive if HR >70 bpm | Not first-line; requires sinus rhythm | | **Furosemide** | Loop diuretic | Class I (for congestion) | Symptom relief only | No mortality benefit | **Clinical Pearl:** Spironolactone is preferred over eplerenone in resource-limited settings (cost). However, monitor potassium and creatinine at baseline, 1 week, and 4 weeks after initiation. Avoid if K^+^ >5.5 mEq/L or eGFR <30 mL/min. **Warning:** Do NOT add amlodipine or other dihydropyridine CCBs to an ACE-I + beta-blocker regimen in systolic HF — they increase mortality risk. Ivabradine is only considered if heart rate remains >70 bpm despite optimal beta-blocker dosing and patient is in sinus rhythm. **Mnemonic — HFrEF Triple Therapy:** **ACE-BB-MRA** (ACE inhibitor → Beta-blocker → Mineralocorticoid Receptor Antagonist). This is the foundational triad; ARNI and SGLT2i are fourth- and fifth-line additions.